Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue results for Q4 and the full year 2024.
For Q4, the company expects revenue of approximately $46.5 million, contributing to a full-year revenue of around $174 million. This meets the top end of their revised guidance, adjusted in Q2 to account for industry-wide challenges.
CEO Michael Egholm highlighted significant progress in reducing operating expenses through the implementation of Standard BioTools Business Systems (SBS). He emphasized the need for continued discipline and improvement. Looking ahead to 2025, the company aims to achieve further efficiencies from integration, enhancing their R&D and shifting revenues towards high-margin offerings.
Egholm expressed optimism about the company's strategy and team, aiming for long-term value for shareholders and customers. The company will report detailed financial results for Q4 and the full year 2024 later this quarter, along with their 2025 outlook.
The preliminary results are subject to completion of annual audit procedures and internal reviews.
Standard BioTools (NASDAQ: LAB) ha annunciato i risultati preliminari e non auditati delle entrate per il quarto trimestre e l'intero anno 2024.
Per il quarto trimestre, l'azienda prevede entrate di circa 46,5 milioni di dollari, contribuendo a un fatturato annuale di circa 174 milioni di dollari. Questo raggiunge il limite superiore delle loro previsioni riviste, aggiornate nel secondo trimestre per tenere conto delle sfide dell'industria.
Il CEO Michael Egholm ha sottolineato i progressi significativi nella riduzione delle spese operative attraverso l'implementazione dei Sistemi Aziendali di Standard BioTools (SBS). Ha enfatizzato la necessità di mantenere una continua disciplina e miglioramento. Guardando al 2025, l'azienda mira a ottenere ulteriori efficienze dall'integrazione, migliorando la loro R&S e spostando le entrate verso offerte ad alta marginalità.
Egholm ha espresso ottimismo riguardo alla strategia e al team dell'azienda, puntando a generare valore a lungo termine per azionisti e clienti. L'azienda fornirà risultati finanziari dettagliati per il quarto trimestre e l'intero anno 2024 più avanti nel trimestre, insieme alle previsioni per il 2025.
I risultati preliminari sono soggetti al completamento delle procedure di audit annuali e delle revisioni interne.
Standard BioTools (NASDAQ: LAB) anunció resultados preliminares y no auditados de ingresos para el cuarto trimestre y el año completo 2024.
Para el cuarto trimestre, la compañía espera ingresos de aproximadamente 46,5 millones de dólares, lo que contribuirá a un ingreso anual de alrededor de 174 millones de dólares. Esto cumple con el límite superior de su guía revisada, ajustada en el segundo trimestre para tener en cuenta los desafíos en la industria.
El CEO Michael Egholm destacó un progreso significativo en la reducción de los gastos operativos mediante la implementación de los Sistemas Empresariales de Standard BioTools (SBS). Enfatizó la necesidad de mantener una disciplina continua y mejorar. Mirando hacia 2025, la empresa tiene como objetivo lograr más eficiencias a través de la integración, mejorando su I+D y trasladando los ingresos hacia ofertas de alto margen.
Egholm expresó optimismo sobre la estrategia y el equipo de la empresa, buscando un valor a largo plazo para los accionistas y clientes. La empresa informará sobre los resultados financieros detallados para el cuarto trimestre y el año completo 2024 más adelante este trimestre, junto con su perspectiva para 2025.
Los resultados preliminares están sujetos a la finalización de los procedimientos de auditoría anual y revisiones internas.
스탠다드 바이오툴스 (NASDAQ: LAB)는 2024년 4분기 및 전체 연도에 대한 예비 감사 비연결 수익 결과를 발표했습니다.
4분기 동안 회사는 약 4650만 달러의 수익을 예상하며, 이는 연간 약 1억7400만 달러의 수익에 기여할 것입니다. 이는 제2분기 업계 전반의 어려움을 고려하여 수정된 지침의 상단 한계에 해당합니다.
CEO 마이클 에굴름은 스탠다드 바이오툴스 비즈니스 시스템(SBS)의 구현을 통해 운영비 절감에서 상당한 성과를 강조했습니다. 그는 지속적인 규율과 개선의 필요성을 강조했습니다. 2025년을 내다보며 회사는 통합을 통한 추가 효율성을 달성하고 R&D를 강화하며 고수익 제품으로 수익을 전환할 것을 목표로 하고 있습니다.
에굴름은 회사의 전략과 팀에 대한 낙관을 표명하며, 주주와 고객을 위한 장기 가치를 추구하고 있습니다. 회사는 이번 분기 말에 4분기 및 2024년 전체 연도의 자세한 재무 결과와 2025년 전망을 발표할 예정입니다.
예비 결과는 연례 감사 절차 및 내부 검토 완료에 따라 달라질 수 있습니다.
Standard BioTools (NASDAQ: LAB) a annoncé des résultats préliminaires et non audités pour les revenus du quatrième trimestre et de l'année entière 2024.
Pour le quatrième trimestre, l'entreprise prévoit des revenus d'environ 46,5 millions de dollars, contribuant à des revenus annuels d'environ 174 millions de dollars. Cela atteint la limite supérieure de leurs prévisions révisées, ajustées au deuxième trimestre pour tenir compte des défis du secteur.
Le PDG Michael Egholm a souligné des progrès significatifs dans la réduction des coûts opérationnels grâce à la mise en œuvre des Systèmes d'Affaires de Standard BioTools (SBS). Il a insisté sur la nécessité d'une discipline continue et d'une amélioration. En regardant vers 2025, l'entreprise vise à réaliser davantage d'efficacités grâce à l'intégration, à améliorer sa R&D et à réorienter les revenus vers des offres à forte marge.
Egholm a exprimé son optimisme quant à la stratégie et à l'équipe de l'entreprise, visant à créer de la valeur à long terme pour les actionnaires et les clients. L'entreprise publiera des résultats financiers détaillés pour le quatrième trimestre et l'année entière 2024 plus tard ce trimestre, ainsi que ses prévisions pour 2025.
Les résultats préliminaires sont soumis à l'achèvement des procédures d'audit annuelles et des examens internes.
Standard BioTools (NASDAQ: LAB) hat vorläufige, ungeprüfte Umsatzahlen für das vierte Quartal und das gesamte Jahr 2024 angekündigt.
Für das vierte Quartal erwartet das Unternehmen einen Umsatz von etwa 46,5 Millionen US-Dollar, was zu einem Gesamtjahresumsatz von rund 174 Millionen US-Dollar beiträgt. Dies erreicht die obere Grenze ihrer revidierten Prognose, die im zweiten Quartal angepasst wurde, um den branchenweiten Herausforderungen Rechnung zu tragen.
CEO Michael Egholm hob die bedeutenden Fortschritte bei der Senkung der Betriebsausgaben durch die Implementierung der Standard BioTools Business Systems (SBS) hervor. Er betonte die Notwendigkeit einer fortwährenden Disziplin und Verbesserung. Ausblick auf 2025 strebt das Unternehmen an, weitere Effizienzen durch Integration zu erzielen, ihre F&E zu verbessern und die Einnahmen in Richtung margenstarker Angebote zu verschieben.
Egholm äußerte Optimismus bezüglich der Strategie und des Teams des Unternehmens und strebt langfristigen Wert für Aktionäre und Kunden an. Das Unternehmen wird später im Quartal detaillierte Finanzdaten für das vierte Quartal und das gesamte Jahr 2024 zusammen mit den Prognosen für 2025 veröffentlichen.
Die vorläufigen Ergebnisse unterliegen der Vollziehung der jährlichen Prüfungsverfahren und internen Überprüfungen.
- Preliminary full-year 2024 revenue of approximately $174 million, meeting the top end of revised guidance.
- Significant progress in reducing operating expenses through Standard BioTools Business Systems (SBS).
- Plans to achieve further efficiencies and shift revenues towards high-margin offerings in 2025.
- Revenue guidance had to be revised in Q2 due to industry-wide challenges.
Insights
Standard BioTools' preliminary
The Q4 revenue of
The implementation of Standard BioTools Business Systems (SBS) for operational efficiency is crucial, as the life sciences tools sector typically requires
The strategic pivot towards high-margin offerings and attractive end markets signals a potential portfolio restructuring. This transition, combined with management's openness to both organic and inorganic growth, suggests possible M&A activity in 2025, particularly given their demonstrated integration capabilities.
The life sciences tools market context is essential for understanding these results. The 'industry-wide headwinds' mentioned likely refer to reduced research funding, cautious spending by pharmaceutical companies and broader economic pressures affecting the sector. The company's strategic focus on high-margin segments aligns with current market trends where premium, specialized tools command better pricing power.
The emphasis on addressing 'technical debt' from both pre-merger companies indicates potential R&D synergies that could materialize in 2025. This is particularly relevant as the life sciences tools market increasingly demands integrated solutions and improved workflow efficiency.
Management's confident tone about future opportunities ('the train has left the station') suggests potential catalysts ahead, but investors should note that the transformation from a traditional tools provider to a high-margin, integrated solutions company typically requires 18-24 months to show meaningful results in the financial metrics.
Preliminary, unaudited revenue for the full year 2024 of approximately
Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of approximately
“The team worked hard in a difficult environment to deliver on the top end of our revised annual guidance forecast, adjusted in the second quarter to account for the ongoing and industry-wide headwinds,” said Michael Egholm, PhD, Chief Executive Officer of Standard BioTools. “We also made significant progress reducing our operating expenses by implementing Standard BioTools Business Systems (“SBS”), but work remains and demands renewed commitment to discipline and continuous improvement.”
Mr. Egholm continued, “Guided by SBS, 2025 will see us realize even more efficiencies from integration, including benefits to R&D as we move past the technical debt inherited from both companies. Consolidations are difficult but our ability to acquire and integrate is clear. It is also clear that now is the time for Standard BioTools to leverage this foundation, organically and inorganically, to scale and shift revenues towards high-margin offerings and attractive end markets.”
“The train has now left the station, with a well-timed, well-capitalized strategy, and a world-class team to deliver long-term value to shareholders and customers alike. The best part of the journey is ahead.”
Standard BioTools plans to report its fourth quarter and full year 2024 financial results later this quarter, at which time the Company will discuss its 2024 financial results in more detail and provide its outlook for 2025.
The Company’s unaudited, preliminary 2024 revenue results are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company’s financial results for the fourth quarter or full year 2024 and remains subject to the completion of financial closing procedures and internal reviews.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue, net loss and adjusted EBITDA; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 1, 2024, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
FAQ
What are the preliminary revenue results for LAB in Q4 2024?
What is the full-year 2024 revenue forecast for Standard BioTools (LAB)?
How did Standard BioTools (LAB) perform against their revised annual guidance for 2024?
What measures did Standard BioTools (LAB) take to reduce operating expenses?
What are Standard BioTools' (LAB) plans for 2025?
When will Standard BioTools (LAB) report its detailed financial results for Q4 and full year 2024?
